Arregui launches air purifiers and expects a turnover of €2.4 million in 2021

Arregui makes the leap to health: the division expects to have a turnover of $2.9 million (€2.4 million) in 2021 Arregui enters the health business. Respirae, the biosafety division of the Basque group, has launched into the market air purifiers that destroy the particles of the Covid-19 through its ultraviolet light technology. 

Arregui’s research and development technician, Carlos Brea, explained that “the forecast is to reach a turnover of $2.9 million (€2.4 million).” The company started in December to commercialize the air purifiers in Spain, Portugal, France and Italy. These are the markets in which Arregui has a presence and supply agreements. Based in Orio (Guipúzcoa), Arregui specializes in developing security solutions, mail and parcel reception, and home equipment. 

If you want to be the first to find the latest breakthroughs in the biotech sector and to read more details about the new air purifier launched by the company Arregui, which destroys Covid 19 particles, download for free the Born2Invest mobile app. Our companion app brings you the latest business news in the world so you can stay informed.

The group estimates it will sell up to 10,000 air purifiers in 2021

These devices consist of a disinfectant that uses ultraviolet light to destroy viruses, bacteria, fungi and other pathogenic microorganisms in the air, such as coronavirus particles. Arregui has started marketing the air purifiers in Spain, Portugal, France and Italy. Brea pointed out that the air purifier is the first device in the biosafety field developed by Arregui and that it was specifically designed to respond to the Covid-19 pandemic.

The company invested more than $218,000 (€180,000) to develop this product. Half of the amount was destined to the incorporation of personnel, while the rest was dedicated to equipment and regulatory processes. The air purifier has an area of fifty square meters and is recommended for closed spaces such as health centers like hospitals and residences, as well as offices, restaurants and gyms. The device has a clean and safe technology, which allows its use in the presence of people. 

Respirae, which is also the name of the device, has an estimated duration of 9,000 hours, which is equivalent to up to four years of continuous operation. Moreover, the device is maintenance-free and easy to operate, as it only has a single on/off button. 

Respirae’s turnover forecast would represent 20% of the group’s global turnover in 2020 Brea also assures that Arregui’s goal is to expand its market. Initially, the company seeks to expand throughout the rest of Europe and then to reach the United States and Latin America. Arregui’s biosafety division is also working on improving the air respirator so that it can cover a larger area. If the forecasts are met, Arregui’s health area would account for 20% of the group’s turnover in 2020, which is $15.2 million (€12.5 million). Gorka Urbieta is the CEO of Arregui, which has almost fifty workers and has offices in Milan.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.